Phase 3
-
Evaluating Novel Therapies in ctDNA Positive GI Cancers
Phase 3 · 20 people · 3 sites in United States · Recruiting now
-
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
Phase 3 · randomised · 254 people · 1 site in France · Recruiting now
-
A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal Cancer
Phase 3 · randomised · 300 people · 1 site in China · Recruiting now
-
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer
Phase 3 · randomised · 600 people · 1 site in Puerto Rico · Recruiting now
-
Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma
Phase 3 · randomised · 1,075 people · 30 sites in France · Recruiting now
-
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
Phase 3 · 30 people · 27 sites in United Kingdom · Recruiting now
-
Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer
Phase 3 · randomised · 180 people · 1 site in China · Recruiting now
-
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Phase 3 · randomised · 550 people · 2 sites in China · Recruiting now
-
SBRT + PD-1 Monoclonal Antibody in Unresectable Colorectal Liver Metastases
Phase 3 · 24 people · 1 site in China · Recruiting now